NDT Pharmaceuticals Inc. (NDTP)
USD 0.07
(-58.27%)
USD 0.07
(-58.27%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -79.03 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | -1240.00 USD | 35.72% |
| 2016 | -1929.00 USD | 97.79% |
| 2015 | -87.33 Thousand USD | 66.5% |
| 2014 | -260.67 Thousand USD | 0.0% |
| 2010 | -246.24 Thousand USD | 0.0% |
| 2007 | -1.03 Million USD | -1902.86% |
| 2006 | -51.76 Thousand USD | -796.6% |
| 2005 | -5773.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1520.00 USD | 44.16% |
| 2024 Q3 | -2200.00 USD | 78.36% |
| 2024 Q2 | -10.16 Thousand USD | -568.82% |
| 2023 Q4 | -2722.00 USD | -32.33% |
| 2023 FY | -79.03 Thousand USD | 0.0% |
| 2023 Q1 | -65.12 Thousand USD | 0.0% |
| 2023 Q2 | -9126.00 USD | 85.99% |
| 2023 Q3 | -2057.00 USD | 77.46% |
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | -1240.00 USD | 35.72% |
| 2016 FY | -1929.00 USD | 97.79% |
| 2015 FY | -87.33 Thousand USD | 66.5% |
| 2014 FY | -260.67 Thousand USD | 0.0% |
| 2011 Q1 | -19.9 Thousand USD | -13.04% |
| 2011 Q2 | -9489.00 USD | 52.33% |
| 2010 Q1 | -12.95 Thousand USD | 0.0% |
| 2010 FY | -246.24 Thousand USD | 0.0% |
| 2010 Q4 | -17.6 Thousand USD | -69.81% |
| 2010 Q3 | -10.36 Thousand USD | 94.95% |
| 2010 Q2 | -205.31 Thousand USD | -1485.3% |
| 2008 Q1 | -20.82 Thousand USD | 97.91% |
| 2008 Q2 | -187.77 Thousand USD | -801.7% |
| 2007 Q3 | -18.14 Thousand USD | -53.75% |
| 2007 FY | -1.03 Million USD | -1902.86% |
| 2007 Q4 | -998.77 Thousand USD | -5405.32% |
| 2007 Q1 | -10.15 Thousand USD | 49.36% |
| 2007 Q2 | -11.8 Thousand USD | -16.23% |
| 2006 Q4 | -20.04 Thousand USD | -159.73% |
| 2006 Q2 | -3761.00 USD | 81.41% |
| 2006 Q1 | -20.23 Thousand USD | 0.0% |
| 2006 Q3 | -7718.00 USD | -105.21% |
| 2006 FY | -51.76 Thousand USD | -796.6% |
| 2005 FY | -5773.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 94.082% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 98.868% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.149% |
| Nascent Biotech, Inc. | -2.08 Million USD | 96.214% |
| Rebus Holdings, Inc. | -1.02 Million USD | 92.252% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.121% |
| Qrons Inc. | -789.34 Thousand USD | 89.988% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 87.503% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.874% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 80.978% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.79% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.895% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 98.798% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 71.093% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.901% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 97.268% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 95.659% |
| Mesoblast Limited | -87.95 Million USD | 99.91% |
| Marizyme, Inc. | -65.34 Million USD | 99.879% |
| Genus plc | 7.9 Million USD | 101.0% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 99.274% |
| Pharming Group N.V. | -10.54 Million USD | 99.251% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 96.358% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 97.87% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 99.106% |
| ContraFect Corporation | -65.15 Million USD | 99.879% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 98.382% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 95.425% |
| IMV Inc. | -36.48 Million USD | 99.783% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 99.019% |
| MultiCell Technologies, Inc. | -380.07 USD | -20694.327% |
| ONE Bio Corp. | 8.67 Million USD | 100.911% |
| Accustem Sciences Inc. | -3.74 Million USD | 97.89% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.847% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 93.763% |
| Q BioMed Inc. | -2.05 Million USD | 96.149% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 97.883% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 96.68% |
| Biomind Labs Inc. | -1.21 Million USD | 93.492% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.868% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 97.452% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 99.0% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 95.945% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -427.731% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.502% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 98.641% |
| GB Sciences, Inc. | -1.36 Million USD | 94.196% |
| Alpha Cognition Inc. | -13.77 Million USD | 99.426% |
| HST Global, Inc. | -146.21 Thousand USD | 45.946% |
| CSL Limited | 2.64 Billion USD | 100.003% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 95.496% |
| Halberd Corporation | -79.67 Thousand USD | 0.807% |
| Enzolytics Inc. | -2.17 Million USD | 96.369% |
| Agentix Corp. | -1.37 Million USD | 94.249% |
| Resverlogix Corp. | -3.61 Million USD | 97.811% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 97.508% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.973% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 180.646% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 101.141% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 98.011% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 97.388% |
| AVAX Technologies, Inc. | -6.41 Million USD | 98.768% |
| Zenith Capital Corp. | -10.59 Million USD | 99.254% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.917% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -240.044% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 98.094% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -30.761% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 96.058% |
| Kadimastem Ltd | -3.3 Million USD | 97.61% |
| Helix BioMedix, Inc. | -1.05 Million USD | 92.516% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 97.931% |
| BioStem Technologies, Inc. | -8.48 Million USD | 99.068% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 82.094% |
| LadRx Corporation | 400.44 Thousand USD | 119.736% |
| Cell Source, Inc. | -5.32 Million USD | 98.515% |
| Regen BioPharma, Inc. | 1.02 Million USD | 107.722% |
| Regen BioPharma, Inc. | 1.02 Million USD | 107.722% |
| NovAccess Global Inc. | -4.76 Million USD | 98.343% |
| Affymax, Inc. | -14.42 Million USD | 99.452% |
| Itoco Inc. | -1.86 Million USD | 95.771% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 98.221% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 95.265% |
| Mobile Lads Corp. | -2.26 Million USD | 96.508% |
| CytoDyn Inc. | -49.84 Million USD | 99.841% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 65.356% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 91.606% |
| SYBLEU INC | -180.3 Thousand USD | 56.167% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 95.099% |
| International Stem Cell Corporation | -131 Thousand USD | 39.669% |
| Bioxytran, Inc. | -4.28 Million USD | 98.153% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -45.624% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 96.876% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.836% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 96.261% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 89.879% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 97.505% |
| Neutra Corp. | -233.46 Thousand USD | 66.148% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.611% |
| PureTech Health plc | -65.69 Million USD | 99.88% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.628% |
| IXICO plc | -1.17 Million USD | 93.291% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 99.204% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.862% |
| CSL Limited | 2.64 Billion USD | 100.003% |
| Cellectis S.A. | -103.17 Million USD | 99.923% |